Partnership to run pre-clinical and double-blind clinical trials using standardized pharmaceutical formulations according to cannabinoids
CAMPINAS, Brazil – March 8, 2021 /Canna Newswire/ – Since its base, NHG Pharmaceuticals has been working discreetly in the highly risky medicinal cannabis market in Brazil.
Structured by Fernando Cesar Mendes, previously in control of New Business Development for its world renowned Dutch firm Green House Seed Co., fiscal entrepreneur Nathan Marcelo Moreira, along with also the American businessman Mark Neeleman, a co-founder of AZUL Brazilian Airlines, on its own board of directors.
Determined by the Brazilian law RDC 327/2019 (ANVISA), that paved the way for the import, manufacture and supply of cannabis-based goods by pharmaceutical firms at Brazil, NHG formalized in the past 12 months exclusive merchandise supply contracts such as API (active pharmaceutical ingredients) and finished pharmaceutical grade products together with just two of the most significant EU-GMP accredited facilities in Europe, situated in Switzerland and the Czech Republic. Furthermore, NHG has also entered into a Joint Venture with Belcher Farmacêutica do Brasil, a multinational firm based in Maringá/PR, that will entail mutual alliance in the import, sales, supply, and research and development of cannabis-based medications in Brazil.
To make sure large-scale distribution capable of providing the enormous Brazilian marketplace, NHG lately signed a LOI with Portuguese giant Symtomax. Approved by INFARMED to commence the process of implementing the farming and export of medical cannabis (raw material and finished goods ), the business is found in the town of Porto, also, using a pre-approved permit of 105 hectares, are the biggest medical cannabis functioning in Europe, working from the creation, study, agriculture, processing and supply of cannabis-based products and medications on the world marketplace.
In the subject of development and research, NHG has signed three major partnership arrangements, among these with Insilicall, the very first Drug Discovery platform from Latin America, which uses artificial intelligence and Big Data in the optimisation of pre-clinical testing, reducing the demand for animal and in vitro testing. NHG, with its medical-scientific group that comprises the Italian physician and prescriber of medicinal cannabis Dr. Lorenzo Calvi, will collaborate with the boosting of information to the development of new formulas for many ailments.
Additionally, through a partnership with Prof. Jean Pierre Schatzmann Peron, associate professor in the Department at Immunology – ICB – USP and G4 associate researcher of the Scientific Platform Pasteur – USP, NHG will run pre-clinical studies employing experimental models with individual neorodegenerative and neuroinflammatory diseases.
The Neuroimmune Interactions Laboratory (ICB/USP) conducts research in the area of immunology, analyzing molecular and cellular mechanisms important in the pathophysiology of infectious diseases, for example Congenital Zika Virus Syndrome, and autoimmune disorders, such as multiple sclerosis. The studies have been conducted in vitro, in cell cultures, and in vivo, in experimental versions.
Primarily, the partnership will run studies in chronic and thoroughly debilitating inflammatory ailments whose remedies continue to be extremely costly or palliative. As a result, the analysis of new therapeutic strategies is essential, and there’s a massive possibility in cannabinoids.
Prof. Jean Pierre’s group has printed over 50 newspapers in high profile foreign journals such as Nature, Nature Immunology and Science, together with over 2300 citations.
As for individual clinical trials, NHG has signed a partnership with UNILA (Federal University of Latin American Integration), through Professor Francisney Nascimento and his staff in the Laboratory of Clinical Neuropharmacology, Department of Medicine, to run double-blind randomized controlled clinical trials with groups of patients with cerebral pathologies.
# CNW #